Authors
Latest:
Colorectal Cancer: A ReviewColorectal cancer is the third most common type of cancer diagnosed in the United States and is the third most common cause of cancer-related death.
Latest:
Dr. Papadimitrakopoulou on Biomarker-Driven Clinical Trials in NSCLCVassiliki Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses biomarker-driven clinical trials in non–small cell lung cancer.
Latest:
Dr. Giri on Genes that Carry a Risk for Prostate CancerVeda Giri, MD, associate professor, Thomas Jefferson University Hospital, discusses genes that are associated with a risk of developing prostate cancer.
Latest:
Dr. Giri on the PROGRESS Registry for Genetic Testing in Prostate CancerVeda N. Giri, MD, discusses the PROGRESS registry in genetic testing and counseling for prostate cancer.
Latest:
Dr. Sondak on Ipilimumab in MelanomaVernon K. Sondak, MD, chair of the Department of Cutaneous Oncology at Moffitt Cancer Center, discusses the use of ipilimumab in the adjuvant setting for patients with melanoma.
Latest:
Dr. Dieras on Combo of Veliparib and Chemotherapy in BRCA1/2-Mutant Breast CancerVéronique Diéras, MD, Department of Clinical Research, Institut Curie Paris & Saint Cloud, discusses results of a phase II trial exploring the combination of the PARP inhibitor veliparib with chemotherapy in patients with BRCA1/2-mutant breast cancer.
Latest:
Dr. Leblond Discusses Treatment After Relapse in CLLVeronique Leblond, MD, head of the Department of Hematology, Pitié Salpêtrière Hospital, Paris, France, discusses the treatment of patients with chronic lymphocytic leukemia (CLL) who have relapsed after initial treatment.
Latest:
Build Referrals and Strengthen RevenuesMultiple resources are available to help community oncologists maintain success by increasing awareness of their practice, providing the most innovative treatments to their patients, and preparing for the future of oncology care.
Latest:
Esserman Helps Push Breast Cancer Prevention Beyond Routine ScreeningsLaura J. Esserman, MD, MBA, a 2018 Giants of Cancer Care® award winner in the Cancer Diagnostics category led the way in designing the I-SPY clinical trials, a groundbreaking effort to match patients with breast cancer to potential therapies based on molecular drivers of disease. She also has advocated for a greater understanding of the biological drivers of breast cancer, rather than relying on mass screening programs, to better analyze early disease.
Latest:
Dr. Keedy Discusses Imaging Biomarkers in OsteosarcomaVicki Keedy, MD, assistant professor of medicine, clinical director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses a trial looking at quantitative imaging biomarkers of treatment response in osteosarcoma.
Latest:
Ongoing Clinical Trials for Patients With Endometrial Cancer: Looking Toward the FutureExperts highlight key ongoing trials and emerging therapies for patients with endometrial cancer.
Latest:
The Future of Endometrial Cancer TreatmentExperts give insight on what they are looking forward to in the endometrial cancer space.
Latest:
Dr. Yazbeck on Idelalisib Plus BR in Relapsed/Refractory CLLVictor Y. Yazbeck, MD, assistant professor, Hematology-Oncology, Internal Medicine, Virginia Commonwealth University (VCU) School of Medicine, VCU Massey Cancer Center, discusses a phase III study examining idelalisib plus bendamustine rituximab in patients with relapsed/refractory chronic lymphocytic leukemia.
Latest:
Dr. Atkinson Discusses BRAF-Mutant Metastatic MelanomaVictoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses the treatment landscape for patients with BRAF-mutant metastatic melanoma.
Latest:
Clinical Scenario: Metastatic EBV-Positive NPCThe panel provides clinical insights on the treatment of a patient with metastatic EBV-positive nasopharyngeal carcinoma.
Latest:
Dr. Villaflor Discusses Alectinib in ALK+ NSCLCVictoria Villaflor, MD, associate professor of medicine, Robert H. Lurie Comprehensive Cancer Center, discusses alectinib (Alecensa) in patients with ALK-positive non–small cell lung cancer.
Latest:
Metformin Plus Chemoradiation Induces Antitumorigenic Immune Response in HNSCCVidhya Karivedu, MD, fellow/resident at the University of Cincinnati College of Medicine, discusses the antitumorigenic immune response seen with the combination of metformin and chemoradiation in patients with locally advanced head and neck squamous cell carcinoma.
Latest:
Smoking Cessation Counseling in Lung Cancer Screening ProgramsThe Lung Cancer Screening Implementation Guide was a product of collaboration among 25 experts from 16 institutions. But it was also a product of both the successes and failures of lung cancer screening programs before it.
Latest:
Dr. Gorantla Addresses Unanswered Questions From the APHINITY TrialVikram C. Gorantla, MD, clinical assistant professor, UPMC Hillman Cancer Center, addresses the unanswered questions following the APHINITY trial in HER2-positive breast cancer.
Latest:
Dr Grünwald on Tumor Burden Outcomes From the CLEAR Trial in Advanced RCCViktor Grünwald, MD, PhD, discusses differences in tumor burden between patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab vs sunitinib.
Latest:
Novel Proteasome Inhibitors for Multiple MyelomaMultiple new proteasome inhibitors currently in clinical or preclinical development bode well for potential future therapies for multiple myeloma, both in frontline and relapsed or refractory settings.
Latest:
Novel Antibody-Drug Conjugate Enters Phase III Trial for Metastatic TNBCInvestigators are optimistic about sacituzumab govitecan (IMMU-132), an antibody–drug conjugate that delivers the chemotherapy metabolite SN-38 to tumor cells expressing the TROP-2 receptor, for patients with relapsed/refractory TNBC.
Latest:
Dr. Chung on Adding Dietary Supplements to Chemotherapy in Pancreatic CancerVincent Chung, MD, discusses findings from a pilot study evaluating the safety of adding dietary supplements to chemotherapy in patients with unresectable pancreatic cancer.
